1-3 of 3
Odeal Pate
Close
Sort by
Journal Articles

Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib.

Nitin Jain, MD, Hagop M. Kantarjian, MD, Carmen Fava, MD, Deborah Thomas, MD, Jan A. Burger, MD, PhD, Gautam Borthakur, MD, Odeal Pate, RN, Jorge Cortes, MD
Journal: Blood
Blood (2007) 110 (11): 1043.
https://doi.org/10.1182/blood.V110.11.1043.1043
Published: 2007
Journal Articles

Immune Modulation of Minimal Residual Disease (MRD) in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CP): A Randomized Trial of Frontline High-Dose (HS) Imatinib Mesylate (IM) with or without Pegylated-Interferon (PEG-IFN) and GM-CSF.

Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Susan O’Brien, MD, Srdan Verstovsek, MD, Charles Asa Koller, MD, Odeal Pate, Jorge Cortes, MD
Journal: Blood
Blood (2006) 108 (11): 2207.
https://doi.org/10.1182/blood.V108.11.2207.2207
Published: 2006
Journal Articles

Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.

Jorge Cortes, M.D., Susan O’Brien, M.D., Srdan Verstovsek, M.D., George Daley, M.D., Charles Koller, M.D., Alessandra Ferrajoli, M.D., Odeal Pate, R.N., Stefan Faderl, M.D., Farhad Ravandi-Kashani, M.D., Moshe Talpaz, M.D., Yali Zhu, Ph.D., Paul Statkevich, Ph.D., Mary Sugrue, M.D., Hagop Kantarjian, M.D.
Journal: Blood
Blood (2004) 104 (11): 1009.
https://doi.org/10.1182/blood.V104.11.1009.1009
Published: 2004